Gyre Therapeutics completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, creating a fully integrated biopharmaceutical company with operations in the U.S. and China. The combined company now has a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including F351 for liver fibrosis and targeted protein degraders from Cullgen. This strategic move strengthens Gyre's leadership and innovation capabilities, supporting future global growth and expanding treatment options for fibrosis and inflammatory diseases. The company is advancing multiple late-stage clinical trials and exploring international development opportunities for its key drug candidates.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
Infrastructure Capital Advisors announced the first monthly dividend of $1 per share for its Infrastructure Capital Nasdaq Option Income ETF (QVOL), targeting an annualized distribution rate of 12-15%. The firm also declared monthly dividends for its...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
